Henry Schein (NASDAQ:HSIC) Price Target Cut to $86.00 by Analysts at Barrington Research

Henry Schein (NASDAQ:HSIC - Free Report) had its price objective reduced by Barrington Research from $90.00 to $86.00 in a report released on Tuesday, MarketBeat reports. They currently have an outperform rating on the stock. Barrington Research also issued estimates for Henry Schein's Q3 2025 earnings at $1.25 EPS, Q4 2025 earnings at $1.29 EPS, FY2025 earnings at $4.85 EPS, Q1 2026 earnings at $1.17 EPS, Q2 2026 earnings at $1.25 EPS, Q3 2026 earnings at $1.35 EPS, Q4 2026 earnings at $1.44 EPS, FY2026 earnings at $5.20 EPS and FY2027 earnings at $5.60 EPS.

A number of other analysts have also recently commented on HSIC. Bank of America upgraded shares of Henry Schein from an "underperform" rating to a "buy" rating and increased their price target for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Jefferies Financial Group upped their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. StockNews.com downgraded shares of Henry Schein from a "buy" rating to a "hold" rating in a report on Thursday, April 17th. Wells Fargo & Company started coverage on shares of Henry Schein in a report on Friday, February 14th. They issued an "equal weight" rating and a $80.00 price target on the stock. Finally, UBS Group reduced their price objective on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $79.30.

Henry Schein Trading Up 0.2 %

Shares of HSIC stock traded up $0.17 on Tuesday, reaching $69.06. The company had a trading volume of 32,825 shares, compared to its average volume of 1,624,042. The company has a 50-day moving average of $67.62 and a 200-day moving average of $71.46. Henry Schein has a 12 month low of $60.56 and a 12 month high of $82.49. The stock has a market cap of $8.46 billion, a PE ratio of 28.42, a PEG ratio of 2.13 and a beta of 0.87. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.04. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.24 billion. During the same period last year, the business posted $1.10 earnings per share. The business's revenue for the quarter was down .1% compared to the same quarter last year. On average, equities analysts forecast that Henry Schein will post 4.74 earnings per share for the current year.

Insider Activity

In other news, Director Philip A. Laskawy sold 2,604 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. The trade was a 9.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.08% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HSIC. Smartleaf Asset Management LLC raised its holdings in shares of Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after buying an additional 143 shares in the last quarter. Guggenheim Capital LLC grew its position in Henry Schein by 2.5% in the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock valued at $445,000 after acquiring an additional 159 shares during the last quarter. CIBC Asset Management Inc raised its stake in Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after acquiring an additional 169 shares in the last quarter. Metis Global Partners LLC lifted its holdings in shares of Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock worth $291,000 after acquiring an additional 187 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Henry Schein by 23.2% in the 1st quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock valued at $73,000 after purchasing an additional 201 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.